Relay Therapeutics Inc (RLAY) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access RLAY Annual Balance Sheets →
The data below summarizes Relay Therapeutics Inc's balance sheet position from Jun 30 2025 to Jun 30 2026, enabling a period-by-period comparison of financial strength.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2026)
(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Assets
Cash & cash equivalent121.19
Marketable Securities789.75
Cash & Short-term Investments910.00
Other Current Assets8.41
Prepaid Expense, Current AS8.74
Total Current Assets928.08
Equipment/Property/Plant Net0.86
Other Assets, Noncurrent38.51
Operating Lease Right Of Use Asset38.59
Total Assets967.46
Liabilities
Accounts Payable, Current AC11.46
Accrued Liabilities, Current AC34.08
Other Liabilities, Current5.27
Total Current Liabilities50.80
Total Long-term Debt0.00
Other liabilities, Noncurrent26.64
Operating Lease Liability Current3.89
Operating Lease Liability Noncurrent27.68
Total Liabilities77.45
Stockholders' Equity
Common Stock Value0.21
Additional Paid In Capital Common Stock3,063.12
Retained Earnings / Accumulated Deficit-2,171.77
Accumulated Other Comprehensive Income-1.55
Other Equity-1.55
Common Stockholder's Equity890.01
Total Stockholder's Equity890.01
Liabilities & Stockholder's Equity967.46
4 historic quarters locked

Sign in to unlock the full Relay Therapeutics Inc balance sheet history.

About Relay Therapeutics Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001193125-26-338056

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.